ERRATUM

Novel compound heterozygous mutations in the *SBP2* gene: characteristic clinical manifestations and the implications of GH and triiodothyronine in longitudinal bone growth and maturation

Takashi Hamajima, Yuichi Mushimoto¹, Hironori Kobayashi¹, Yoshiro Saito² and Kaxumichi Onigata¹

The journal apologises for an error in Figure 3 of this article published in the *European Journal of Endocrinology* 166 757–764. The two shaded bars showing the duration of GH and T₃ treatment in Figure 3 were inadvertently missed out. The correct figure is published in full below.

European Journal of Endocrinology 166 957

Figure 3 Growth chart and bone age of the patient. Black filled circles show height and body weight. Gray circles show bone age. The two shaded bars show the duration of GH and T₃ treatments. Arrows indicate the gap between chronological age and bone age. Height velocity apparently increased after initiating the GH treatment; however, a gap of approximately 3 years between chronological age and bone age remained until the commencement of T₃ treatment. Six months of T₃ treatment with GH decreased the gap. We obtained permission to use the growth chart for Japanese boys based on a cross-sectional survey in 2000 (29).